Scandinavia Pharmaceuticals Market Summary, Competitive Analysis and Forecast to 2026
Scandinavia Pharmaceuticals Market @Summary, Competitive Analysis and Forecast to 2026
SUMMARY
Pharmaceuticals in Scandinavia industry profile provides top-line qualitative and quantitative summary information including: market size (value 2016-21, and forecast to 2026). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
KEY HIGHLIGHTS
SUMMARY
Pharmaceuticals in Scandinavia industry profile provides top-line qualitative and quantitative summary information including: market size (value 2016-21, and forecast to 2026). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
KEY HIGHLIGHTS
- The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare.
- The Scandinavian pharmaceuticals market had total revenues of $15.9 billion in 2021, representing a compound annual growth rate (CAGR) of 3.0% between 2016 and 2021.
- Scandinavian markets are currently facing a growing threat from Asian nations such as China and India, whose manufacturing capacities have increased recently and who also provide lower labor and tax exemptions.
- Scandinavian countries are typically perceived to be among the healthiest in Europe. Food consumption in this region tends to be focused heavily on fish, vegetables, and whole grains, all of which have significant health benefits.
- Save time carrying out entry-level research by identifying the size, growth, and leading players in the pharmaceuticals market in Scandinavia
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in Scandinavia
- Leading company profiles reveal details of key pharmaceuticals market players’ global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the Scandinavia pharmaceuticals market with five year forecasts
- What was the size of the Scandinavia pharmaceuticals market by value in 2021?
- What will be the size of the Scandinavia pharmaceuticals market in 2026?
- What factors are affecting the strength of competition in the Scandinavia pharmaceuticals market?
- How has the market performed over the last five years?
1 EXECUTIVE SUMMARY
1.1. Market value
1.2. Market value forecast
1.3. Geography segmentation
1.4. Market share
1.5. Market rivalry
1.6. Competitive Landscape
2 MARKET OVERVIEW
2.1. Market definition
2.2. Market analysis
3 MARKET DATA
3.1. Market value
4 MARKET SEGMENTATION
4.1. Geography segmentation
5 MARKET OUTLOOK
5.1. Market value forecast
6 FIVE FORCES ANALYSIS
6.1. Summary
6.2. Buyer power
6.3. Supplier power
6.4. New entrants
6.5. Threat of substitutes
6.6. Degree of rivalry
7 COMPETITIVE LANDSCAPE
7.1. Market share
7.2. Who are the leading players?
7.3. What strategies do leading players follow?
7.4. How have leading players responded to the COVID-19 pandemic?
7.5. Are there any threats toward leading players?
8 COMPANY PROFILES
8.1. Novartis AG
8.2. Sanofi SA
8.3. F. Hoffmann-La Roche Ltd
8.4. Pfizer Inc.
9 MACROECONOMIC INDICATORS
9.1. Country data
10 APPENDIX
10.1. Methodology
10.2. Industry associations
10.3. Related MarketLine research
10.4. About MarketLine
1.1. Market value
1.2. Market value forecast
1.3. Geography segmentation
1.4. Market share
1.5. Market rivalry
1.6. Competitive Landscape
2 MARKET OVERVIEW
2.1. Market definition
2.2. Market analysis
3 MARKET DATA
3.1. Market value
4 MARKET SEGMENTATION
4.1. Geography segmentation
5 MARKET OUTLOOK
5.1. Market value forecast
6 FIVE FORCES ANALYSIS
6.1. Summary
6.2. Buyer power
6.3. Supplier power
6.4. New entrants
6.5. Threat of substitutes
6.6. Degree of rivalry
7 COMPETITIVE LANDSCAPE
7.1. Market share
7.2. Who are the leading players?
7.3. What strategies do leading players follow?
7.4. How have leading players responded to the COVID-19 pandemic?
7.5. Are there any threats toward leading players?
8 COMPANY PROFILES
8.1. Novartis AG
8.2. Sanofi SA
8.3. F. Hoffmann-La Roche Ltd
8.4. Pfizer Inc.
9 MACROECONOMIC INDICATORS
9.1. Country data
10 APPENDIX
10.1. Methodology
10.2. Industry associations
10.3. Related MarketLine research
10.4. About MarketLine
LIST OF TABLES
Table 1: Scandinavia pharmaceuticals market value: $ billion, 2016–21
Table 2: Scandinavia pharmaceuticals market geography segmentation: $ billion, 2021
Table 3: Scandinavia pharmaceuticals market value forecast: $ billion, 2021–26
Table 4: Scandinavia pharmaceuticals market share: % share, by value, 2021
Table 5: Novartis AG: key facts
Table 6: Novartis AG: Annual Financial Ratios
Table 7: Novartis AG: Key Employees
Table 8: Novartis AG: Key Employees Continued
Table 9: Sanofi SA: key facts
Table 10: Sanofi SA: Annual Financial Ratios
Table 11: Sanofi SA: Key Employees
Table 12: Sanofi SA: Key Employees Continued
Table 13: F. Hoffmann-La Roche Ltd: key facts
Table 14: F. Hoffmann-La Roche Ltd: Annual Financial Ratios
Table 15: F. Hoffmann-La Roche Ltd: Key Employees
Table 16: Pfizer Inc.: key facts
Table 17: Pfizer Inc.: Annual Financial Ratios
Table 18: Pfizer Inc.: Key Employees
Table 19: Pfizer Inc.: Key Employees Continued
Table 20: Scandinavia exchange rate, 2017–21
Table 1: Scandinavia pharmaceuticals market value: $ billion, 2016–21
Table 2: Scandinavia pharmaceuticals market geography segmentation: $ billion, 2021
Table 3: Scandinavia pharmaceuticals market value forecast: $ billion, 2021–26
Table 4: Scandinavia pharmaceuticals market share: % share, by value, 2021
Table 5: Novartis AG: key facts
Table 6: Novartis AG: Annual Financial Ratios
Table 7: Novartis AG: Key Employees
Table 8: Novartis AG: Key Employees Continued
Table 9: Sanofi SA: key facts
Table 10: Sanofi SA: Annual Financial Ratios
Table 11: Sanofi SA: Key Employees
Table 12: Sanofi SA: Key Employees Continued
Table 13: F. Hoffmann-La Roche Ltd: key facts
Table 14: F. Hoffmann-La Roche Ltd: Annual Financial Ratios
Table 15: F. Hoffmann-La Roche Ltd: Key Employees
Table 16: Pfizer Inc.: key facts
Table 17: Pfizer Inc.: Annual Financial Ratios
Table 18: Pfizer Inc.: Key Employees
Table 19: Pfizer Inc.: Key Employees Continued
Table 20: Scandinavia exchange rate, 2017–21
LIST OF FIGURES
Figure 1: Scandinavia pharmaceuticals market value: $ billion, 2016–21
Figure 2: Scandinavia pharmaceuticals market geography segmentation: % share, by value, 2021
Figure 3: Scandinavia pharmaceuticals market value forecast: $ billion, 2021–26
Figure 4: Forces driving competition in the pharmaceuticals market in Scandinavia, 2021
Figure 5: Drivers of buyer power in the pharmaceuticals market in Scandinavia, 2021
Figure 6: Drivers of supplier power in the pharmaceuticals market in Scandinavia, 2021
Figure 7: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Scandinavia, 2021
Figure 8: Factors influencing the threat of substitutes in the pharmaceuticals market in Scandinavia, 2021
Figure 9: Drivers of degree of rivalry in the pharmaceuticals market in Scandinavia, 2021
Figure 10: Scandinavia pharmaceuticals market share: % share, by value, 2021
Figure 1: Scandinavia pharmaceuticals market value: $ billion, 2016–21
Figure 2: Scandinavia pharmaceuticals market geography segmentation: % share, by value, 2021
Figure 3: Scandinavia pharmaceuticals market value forecast: $ billion, 2021–26
Figure 4: Forces driving competition in the pharmaceuticals market in Scandinavia, 2021
Figure 5: Drivers of buyer power in the pharmaceuticals market in Scandinavia, 2021
Figure 6: Drivers of supplier power in the pharmaceuticals market in Scandinavia, 2021
Figure 7: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Scandinavia, 2021
Figure 8: Factors influencing the threat of substitutes in the pharmaceuticals market in Scandinavia, 2021
Figure 9: Drivers of degree of rivalry in the pharmaceuticals market in Scandinavia, 2021
Figure 10: Scandinavia pharmaceuticals market share: % share, by value, 2021
